Curtis Dunshee

Statistics

Publications

Citations

1.7K

H-Index

Active since

1992

Affiliations

Pfizer (United States)(Current)

Huntsman Cancer Institute

Carolina Urologic Research Center

Institut Gustave Roussy

Peter MacCallum Cancer Centre

Curtis Dunshee is an author at Pfizer (United States) specializing in medicine, genitourinary cancer pharmacotherapy, and metastatic castration-resistant prostate cancer.

ORCID

Publications per year

1992–2025

Publications

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

Neeraj Agarwal, Arun Azad, Joan Carles et al. · The Lancet · 2023 · 499 citations

Medicine, Pharmacology, Pharmacotherapy +12

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Kim N., Dana E. Rathkopf, Matthew R. Smith et al. · Journal of Clinical Oncology · 2023 · 319 citations · Full text

Medicine, Oncology, Urology +17

Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial

David F. Penson, Andrew J. Armstrong, Raoul S. Concepcion et al. · Journal of Clinical Oncology · 2016 · 315 citations

Medicine, Oncology, Pharmacology +17

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Karim Fizazi, Arun Azad, Nobuaki Matsubara et al. · Nature Medicine · 2023 · 127 citations · Full text

Medicine, Oncology, Pharmacology +17

Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study

Arnulf Stenzl, Curtis Dunshee, Ugo De Giorgi et al. · European Urology · 2020 · 56 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

1–5 of 20